Sustainable revenue growth in the Advanced Research and Development Support Business and the early establishment of the Healthcare Solutions Business
First written in FY2021. 8 of 17 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026ReframedAnnual report
「Based on these considerations, we formulated the five-year medium-term management plan [TIAD6]. Under TIAD6, we will establish and implement priority strategies addressing the following 5 challenges.」
The strategic framework was changed from the previous two-business structure of the Advanced Research and Development Support Business and the Healthcare Solutions Business to TIAD6, centered on 5 challenges: maintaining and expanding existing businesses, expanding business areas, technological competitiveness, productivity, and human capital. - FY2026-H1ReframedAnnual report
「Through this change, we will accelerate our group’s future growth by using limited resources more flexibly and organically and allocating them intensively to strategic areas, thereby making efficient research and development investments, reliably launching new businesses, and expanding high-value-added businesses, leading to enhanced corporate value.」
The framework was changed from disclosure centered on the Advanced Research and Development Support Business and the Healthcare Solutions Business to an explanation focused on concentrating limited resources on strategic areas, new businesses, and high-value-added businesses. - FY2025-H1Higher revenue but lower profit in the core business; the Healthcare Business turned profitable.Annual report
「As a result, total segment revenue was ¥527.801 million, up 2.1% year on year. Concentrated investment in research and development for the productivity improvement support service for bio-manufacturing increased segment expenses, resulting in segment profit after the allocation of company-wide expenses of ¥76.052 million, down 19.6% year on year. As a result, revenue was ¥156.680 million, up 35.2% year on year. The shift in research and development investment to the Advanced Research and Development Support Business substantially reduced segment expenses, resulting in segment profit after the allocation of company-wide expenses of ¥28.550 million, compared with a segment loss of ¥23.025 million in the same period of the previous year.」
While the Advanced Research and Development Support Business reported higher revenue but lower profit, the Healthcare Solutions Business benefited from lower expenses following the shift in research and development investment, and achieved higher revenue and a return to profit, recording segment profit of ¥28.550 million. - FY2024Lower revenue and profit in the core business; higher revenue and a smaller loss in the Healthcare Business.Annual report
「The medium-term management plan for the fiscal years ending June 2024 through June 2026 aims for steady revenue and profit growth in the Advanced Research and Development Support Business pursued to date, while positioning this period as one for building the business foundation needed to expand and monetize the Healthcare Solutions Business.」
The medium-term management strategy remains in place. In FY2024, while the Advanced Research and Development Support Business reported lower revenue and profit, the Healthcare Solutions Business recorded revenue of ¥158.818 million and a loss of ¥90.532 million, indicating higher revenue and a smaller loss. - FY2024-Q3The core business reported lower revenue and profit, while the Healthcare Business posted a substantial increase in revenue and a smaller loss.Annual report
「As a result, revenue was ¥963.363 million, down 7.9% year on year, and segment profit after the allocation of company-wide expenses was ¥299.387 million, down 19.8% year on year. As a result, revenue was ¥152.192 million, up 415.6% year on year, and the segment loss after the allocation of company-wide expenses was ¥47.446 million, compared with a segment loss of ¥110.321 million in the same period of the previous year.」
While the Advanced Research and Development Support Business reported lower revenue and profit, the Healthcare Solutions Business recorded a substantial increase in revenue, and its segment loss narrowed from the same period of the previous year. - FY2024-Q2Revenue declined in the core business, while the Healthcare Business improved.Annual report
「As a result, revenue was ¥516.990 million, down 12.0% year on year, and segment profit after allocation of corporate expenses was ¥94.565 million, down 38.5%.」
While the Advanced Research and Development Support Business reported lower revenue and profit, the Healthcare Solutions Business won a large paid joint development project and recorded revenue of ¥115.910 million and a segment loss of ¥23.025 million. Progress in the two businesses has diverged. - FY2023AdvancedAnnual report
「The medium-term management plan for the fiscal years ending June 2024 through June 2026, [Challenge to Healthcare Value Innovator 25], continues the strategy for the Advanced Research and Development Support Business pursued to date, aims for steady revenue and profit growth in that segment, and positions this period as one for building the business foundation needed for the dramatic expansion of the Healthcare Solutions Business, the company’s growth engine.」
The medium-term management strategy for the two businesses was given concrete form under a new planning period and plan name, with revenue and profit growth in the Advanced Research and Development Support Business and the establishment of a foundation for the Healthcare Solutions Business presented as the next stage. - FY2023-Q3AdvancedAnnual report
「As a result, revenue was ¥1,045.761 million, up 3.8% year on year, and segment profit after allocation of corporate expenses was ¥373.253 million, up 4.1%.」
For the Advanced Research and Development Support Business, the core business under the medium-term management strategy, the company reported higher revenue and profit. - FY2023-Q2AdvancedAnnual report
「As a result, revenue was ¥587.789 million, up 10.6% year on year, and segment profit after allocation of corporate expenses was ¥153.646 million, up 15.4%.」
For the Advanced Research and Development Support Business, the core business under the medium-term management strategy, the company reported higher revenue and profit. - FY2023-Q1AdvancedAnnual report
「As a result, revenue was ¥255.674 million, up 47.3% year on year, and segment profit after allocation of corporate expenses was ¥38.684 million, compared with a segment loss of ¥19.596 million in the same period of the previous year.」
For the Advanced Research and Development Support Business, the core business under the medium-term management strategy, the company reported higher revenue and a return to profit from a segment loss. - FY2022AdvancedAnnual report
「Our group’s medium-term management strategy is to achieve sustained earnings growth in the Advanced Research and Development Support Business, our core business, and establish the Healthcare Solutions Business at an early stage. In the Advanced Research and Development Support Business, we will further enhance operational excellence by expanding our new service offerings and improving productivity.」
The medium-term management strategy for the two businesses continued, with the Advanced Research and Development Support Business expanding its service offerings and improving productivity, and recording segment profit of ¥331.992 million. - FY2022-Q3AdvancedAnnual report
「As a result, revenue was ¥1,007.483 million, up 9.1% year on year, and segment profit was ¥358.589 million, up 101.6%.」
Revenue and segment profit in the Advanced Research and Development Support Business increased, providing numerical evidence of expanding earnings in the core business. - FY2022-Q2AdvancedAnnual report
「As a result, revenue was ¥531.565 million, down 0.7% year on year, and segment profit after allocation of corporate expenses was ¥133.117 million, up 125.7%.」
The Advanced Research and Development Support Business recorded segment profit of ¥133.117 million, up 125.7% year on year, providing numerical evidence of expanding earnings in the core business. - FY2022-Q1AdvancedAnnual report
「From the first quarter of the current consolidated fiscal year, the Company changed its reportable segments, in line with changes in its management policies and strategy, from the former Metabolomics Business and Biomarker Business to the Advanced R&D Support Business and Healthcare Solutions Business.」
The medium-term management strategy based on the two pillars of the advanced research and development support business and the healthcare solutions business moved into the implementation phase through the change in reportable segments. - FY2021First statedAnnual report
「The Group's medium-term management strategy is to achieve sustainable earnings growth in its core Advanced Research and Development Support Business, including the Metabolomics Business and new contract analysis services through the fiscal year ending June 2021, and to establish its Healthcare Solutions Business at an early stage, including the Biomarker Business and new businesses through the fiscal year ending June 2021.」
The Company reorganized its existing metabolomics and biomarker businesses into two business areas, including new contracted analysis services and new businesses, and disclosed for the first time, as separate medium-term management strategies, the expansion of earnings in each area and their early establishment.